Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]-BIIB091 in Healthy Men
NCT06311786Phase 1Completed
- Sponsor
- Biogen
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of biib091 in multiple sclerosis (MS), sponsored by Biogen. Primary endpoints: Amount of BIIB091 Excreted in Urine at Day 10, Amount of BIIB091 Excreted in Feces at Day 10 and 14 more. Started Apr 2024; status: completed.
02
Drugs
biib091
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT06311786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06311786.